By Metrologie Solutions Philippines   |   Pharmaceutical Cold Chain Compliance Experts   |   Updated 2025

If you are a pharmaceutical manufacturer, drug importer, distributor, wholesaler, or even a drugstore in the Philippines, there is one document that should be at the centre of your quality and compliance programme: FDA Circular No. 2021-003.

Issued by the Food and Drug Administration of the Philippines and formally titled ‘Revised Guidelines on the Cold Chain Management for Pharmaceutical Products and Establishments,’ this circular is the primary domestic legal framework governing how temperature-sensitive pharmaceutical products must be stored, handled, transported, and validated in the Philippines.

Yet despite its critical importance, FDA Circular 2021-003 remains one of the most misunderstood and underimplemented regulatory documents in the Philippine pharmaceutical industry. Many establishments know the circular exists. Far fewer have fully understood what it actually requires — especially when it comes to thermal mapping, the scientific validation process that sits at the heart of its temperature control obligations.

This article provides the most comprehensive, plain-language analysis of FDA Circular 2021-003 available for Philippine pharmaceutical businesses in 2025. It explains exactly what the circular covers, who it applies to, what it requires, and — most importantly — what your establishment must do right now to achieve and maintain full compliance, with particular focus on the thermal mapping obligations that determine whether your Licence to Operate is granted, renewed, or suspended.

What You Will Know After Reading This ArticleExactly which establishments are covered by FDA Circular 2021-003 — and why the scope is wider than many companies realiseThe specific cold chain infrastructure requirements the circular mandatesThe temperature validation and thermal mapping obligations that underpin LTO complianceThe documentation the FDA will look for during an inspectionHow FDA Circular 2021-003 connects to WHO Good Distribution Practice guidelinesA practical compliance roadmap for Philippine drug companies at every stage of readiness

1. Background: Why FDA Circular 2021-003 Was Issued

To understand why FDA Circular 2021-003 matters, it helps to understand the problem it was designed to solve.

For decades, the Philippine pharmaceutical cold chain operated under guidelines that were designed for a simpler era — primarily BFAD Circular No. 2007-003, which focused largely on vaccine storage and the specific requirements of the national immunisation programme. As the Philippine pharmaceutical market grew in complexity — with a rapidly expanding portfolio of biologics, insulin products, oncology drugs, and other temperature-sensitive specialty medicines — the 2007 guidelines became increasingly inadequate as a comprehensive regulatory framework.

At the same time, international regulatory standards evolved significantly. The World Health Organization published updated Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products (WHO TRS 961 Annex 9) in 2011 and has continued to update its technical supplements since then. The International Society for Pharmaceutical Engineering released its revised Good Practice Guide for Controlled Temperature Chambers in 2021. Global pharmaceutical companies operating in the Philippines began demanding higher cold chain standards from their local distribution partners.

FDA Circular 2021-003 was the Philippine FDA’s response to this evolving landscape. Issued in March 2021, it updated, expanded, and modernised the country’s cold chain management requirements for pharmaceutical products — aligning Philippine practice with international standards while establishing clear, enforceable obligations for the full range of pharmaceutical establishments operating in the country.

What Changed from the Previous Guidelines

The 2021 circular represented a significant upgrade from BFAD Circular 2007-003 in several important ways:

• Wider scope of covered establishments — the 2021 circular applies not only to cold chain-specific distributors but to the full range of drug establishments including manufacturers, importers, exporters, wholesalers, traders, and retail pharmaceutical outlets
• Stronger validation requirements — the circular explicitly requires that storage areas be qualified before use, moving beyond simple temperature monitoring to require the documented validation of storage environments
• Explicit alignment with WHO standards — the 2021 circular references and incorporates WHO Good Distribution Practice guidelines, making compliance with international cold chain standards a Philippine regulatory requirement
• Broader product scope — coverage extends beyond vaccines and biologics to encompass all pharmaceutical products requiring temperature-controlled storage
• Strengthened documentation requirements — more detailed record-keeping obligations for temperature logs, calibration certificates, SOPs, and deviation investigations

2. Who Does FDA Circular 2021-003 Apply To?

One of the most important — and most commonly misunderstood — aspects of FDA Circular 2021-003 is its scope of coverage. The circular applies to a significantly wider range of pharmaceutical establishments than many Philippine companies realise.

The circular covers all establishments involved in the handling, storage, distribution, or dispensing of pharmaceutical products that require temperature-controlled conditions. This includes:

Establishment Type	Coverage Under FDA Circular 2021-003	Key Cold Chain Obligation
Drug Manufacturers	Fully covered — all manufacturing, in-process and finished product storage	Qualification of all temperature-controlled manufacturing and storage areas; GMP compliance
Drug Importers	Fully covered — from port of entry through receipt at warehouse	Port of entry cold chain management; immediate qualified storage upon receipt
Drug Exporters	Fully covered — staging and export cold chain management	Validated storage and export documentation
Drug Wholesalers / Distributors	Fully covered — primary target of the circular’s distribution requirements	Warehouse qualification; thermal mapping; continuous monitoring; SOP compliance
Drug Traders	Covered — even if not physically handling products	Ensuring that contracted storage and distribution partners are compliant
Drugstores / Pharmacies	Covered for products requiring cold storage (vaccines, biologics, etc.)	Cold chain-capable storage equipment; temperature monitoring; SOP for cold chain products
Hospital / Institutional Pharmacies	Covered — for all temperature-sensitive pharmaceutical products	Qualified refrigerator/cold room storage; continuous monitoring; calibrated equipment
Retail Outlets (RONPD)	Covered for any temperature-sensitive OTC products handled	Basic cold chain compliance for products requiring temperature control
3PL Cold Chain Providers	Covered when handling pharmaceutical products as contracted partner	Full warehouse qualification; thermal mapping; GDP-compliant operations

Don’t Assume You Are Not CoveredA common compliance gap in the Philippine pharmaceutical industry is the assumption that FDA Circular 2021-003 applies only to ‘cold chain companies’ — establishments specifically licensed for cold chain distribution.In reality, any establishment whose Licence to Operate includes the handling, storage, or distribution of pharmaceutical products that require temperature control — including ordinary drugstores carrying vaccines and biologics — falls within the scope of the circular. FDA inspectors do not limit their temperature compliance review to cold chain specialists.

3. The Core Requirements of FDA Circular 2021-003

The circular establishes requirements across several interconnected domains. Understanding each domain — and how they interact — is essential for building a genuinely compliant pharmaceutical cold chain operation in the Philippines.

3.1 Temperature-Controlled Infrastructure Requirements

FDA Circular 2021-003 requires that pharmaceutical establishments maintain storage infrastructure appropriate to the temperature requirements of the products they handle. This is not simply a matter of having a refrigerator — it requires infrastructure that is designed, constructed, and qualified to maintain the required temperatures under all foreseeable operating conditions.

For different product categories, the infrastructure requirements differ:

• Cold storage (2°C to 8°C): Dedicated pharmaceutical-grade cold rooms or refrigerators for products including vaccines, biologics, insulin, and refrigerated antibiotics. Consumer-grade refrigerators are explicitly not acceptable for pharmaceutical products requiring strict temperature control.
• Controlled room temperature (15°C to 30°C): Climate-controlled storage areas for the majority of pharmaceutical products. In the Philippine climate, achieving and maintaining this range in large warehouses requires validated HVAC infrastructure.
• Frozen storage (-15°C to -25°C or colder): Walk-in freezers or pharmaceutical-grade chest freezers for plasma, certain vaccines, and specific biologics.
• Backup power: The circular requires that establishments have contingency provisions — including generator sets and voltage regulators — to maintain temperature during power interruptions. This requirement is particularly relevant in the Philippines, where power interruptions outside Metro Manila remain a significant cold chain risk.

3.2 Equipment Qualification and Thermal Mapping

This is the most technically demanding requirement of FDA Circular 2021-003, and the one that most Philippine pharmaceutical establishments are least prepared for.

The circular requires that all temperature-controlled storage areas be properly qualified before use. In plain language: before you store any pharmaceutical product in a cold room, warehouse, or refrigerator, you must demonstrate through a documented study that the storage equipment or area actually maintains the required temperature throughout its entire volume under real operating conditions.

This is the thermal mapping requirement. Although the circular aligns with WHO Good Distribution Practice guidelines that use this term explicitly, the obligation is clear regardless of terminology: documentary evidence of temperature qualification is required.

The WHO standards referenced by the circular — particularly WHO TRS 961 Annex 9 and its Supplement 8 — specify what this qualification must demonstrate:

1. The air temperature profile throughout the storage area, both when empty and when loaded with product
2. Identification of hot spots (areas prone to temperature elevation) and cold spots (areas prone to excessive cooling)
3. Zones within the storage area that must not be used for product storage due to temperature extremes
4. The time taken for temperatures to exceed specified limits when cooling equipment fails (power failure test)
5. Confirmation that the storage area can maintain the required temperature range consistently over the study period

The qualification study must be documented in a formal report that includes the study protocol, the calibration certificates of all measurement equipment used, sensor placement records, raw temperature data, analysis of results, identification of hot and cold spots, and conclusions with approval signatures.

This qualification must be repeated whenever significant changes are made to the storage infrastructure, and should be conducted periodically (typically every one to two years) even without changes, to demonstrate continuing compliance.

3.3 Continuous Temperature Monitoring

Beyond the initial qualification, FDA Circular 2021-003 requires continuous monitoring of temperature conditions in all pharmaceutical storage areas during normal operations. This means:

• Permanently installed temperature sensors or data loggers in all storage areas
• Continuous recording of temperature at regular intervals (typically every 5 to 30 minutes)
• Alarm systems that alert designated personnel when temperatures go outside the specified range
• A backup monitoring system or documented contingency procedure to ensure continuity of monitoring during equipment failure
• Maintenance of complete temperature logs that are available for inspection by FDA officers

Critically, the circular’s requirement for continuous monitoring must be read together with the qualification requirement: monitoring sensors must be positioned based on the results of the thermal mapping study — specifically at the hot spots and cold spots identified by that study. Monitoring sensors placed by guesswork, rather than by mapping data, are not providing meaningful worst-case surveillance of the storage environment.

3.4 Calibration Requirements

The circular requires that all temperature monitoring and control equipment be regularly calibrated. Calibration must be against a traceable reference standard — in the Philippine context, this means calibration by a laboratory accredited by the Philippine Accreditation Bureau (PAB) to ISO/IEC 17025, ensuring traceability through the national measurement infrastructure.

Calibration certificates must be maintained and made available for FDA inspection. The WHO guidelines referenced by the circular recommend calibration at least once a year; for high-risk products, more frequent calibration (every six months) is best practice and increasingly expected.

3.5 Standard Operating Procedures (SOPs)

FDA Circular 2021-003 requires that covered establishments maintain written, approved, and implemented Standard Operating Procedures for all cold chain activities. The SOPs required include:

• Maintenance and care of cold chain equipment (cold rooms, freezers, refrigerators)
• Temperature monitoring and adjustment procedures
• Cold chain procedures from origin through port of entry to storage and distribution
• Transport cold chain management including validation studies for transport containers
• Procedures for loading and staging of temperature-sensitive products
• Handling of product complaints and product recalls
• Emergency and contingency procedures for cold chain failures, power interruptions, and equipment malfunctions
• Procedures for handling and investigating temperature excursions
• Product disposition procedures — criteria for quarantine, retention, and destruction of potentially compromised products

3.6 Personnel Training

The circular requires that all personnel involved in cold chain operations be properly trained in their responsibilities, in the relevant procedures, and in emergency response. Training records must be documented and available for inspection. For establishments handling frozen products, the circular requires that personnel have appropriate protective equipment (warm clothing, gloves) and understand the specific safety and handling requirements for frozen pharmaceutical products.

3.7 Record Keeping and Documentation

Documentation is the foundation of regulatory compliance — and FDA Circular 2021-003 is explicit about the records that must be maintained. Required records include:

• Temperature logs for all storage areas — continuous records of temperature readings during the full storage period
• Calibration certificates for all monitoring equipment — current and historical
• Equipment qualification reports — thermal mapping studies, with all supporting documentation
• SOP approval and revision records
• Training records for all cold chain personnel
• Temperature excursion logs — records of all excursion events, investigations, corrective actions, and product disposition decisions
• Maintenance records for cold chain equipment
• Transport cold chain records — for establishments involved in product distribution

4. How FDA Circular 2021-003 Connects to WHO GDP and International Standards

One of the most significant aspects of FDA Circular 2021-003 is its explicit alignment with WHO Good Distribution Practice guidelines. Understanding this connection is essential — because it means that compliance with the Philippine circular effectively requires compliance with international pharmaceutical distribution standards.

The WHO GDP Framework

WHO Good Distribution Practice (GDP) guidelines — published in WHO Technical Report Series No. 961 Annex 9 and updated in WHO TRS 1010 Annex 7 — provide the global standard for pharmaceutical storage and distribution. They cover all aspects of cold chain management from facility qualification through transport validation, and they are the reference framework used by regulatory agencies throughout Southeast Asia and globally.

The Philippine FDA’s alignment with WHO GDP means that a Philippine pharmaceutical establishment fully compliant with FDA Circular 2021-003 is operating to international standards — making it attractive not only to domestic regulators but to international pharmaceutical principals, export markets, and third-party auditors.

WHO TRS 961 Annex 9: The Facility Qualification Standard

The WHO requirement that all new temperature-controlled storage areas be qualified before operational use — and that qualification be repeated after modifications — is directly incorporated into the Philippine regulatory framework through the FDA’s reference to WHO guidelines. This means the WHO methodology for conducting qualification studies (thermal mapping) is not merely a best practice for Philippine establishments — it is a compliance requirement.

WHO TRS 961 Supplement 8: The Thermal Mapping Methodology

Supplement 8 to WHO TRS 961, specifically focused on temperature mapping of storage areas, provides the detailed technical specification for how mapping studies must be conducted. This includes requirements for protocol development, sensor selection and placement, data logger calibration, study duration, data analysis, and report format. Philippine establishments conducting thermal mapping studies in accordance with this supplement are producing documentation that meets both local FDA and international WHO standards simultaneously.

The ISPE Good Practice Guide

The International Society for Pharmaceutical Engineering’s Good Practice Guide: Controlled Temperature Chambers (Second Edition, 2021) is the industry technical standard that complements the WHO regulatory framework. Many multinational pharmaceutical companies distributing products in the Philippines require their local partners to conduct thermal mapping studies aligned with the ISPE guide. Philippine establishments that use the ISPE framework for their mapping studies produce documentation that satisfies both the Philippine FDA and international principal requirements.

Standard / Guideline	Issued By	Relationship to FDA Circular 2021-003	Thermal Mapping Requirement
WHO TRS 961 Annex 9	WHO	Referenced by Philippine FDA; compliance required	Mandatory qualification of all storage areas before use
WHO TRS 961 Supplement 8	WHO	Referenced by Philippine FDA; compliance required	Detailed protocol, sensor placement, data analysis, report standards
WHO TRS 1010 Annex 7	WHO	2021 update; strengthens transport requirements	Consistent mapping methodology for warehouses and transport
ISPE GPG CTC (2021)	ISPE	Industry standard; required by many MNC principals	Full commissioning and qualification mapping lifecycle
AO 2024-0015	FDA PH	Updated LTO requirements effective January 2025	Thermal mapping documentation required for LTO compliance
GMP/PIC/S	PIC/S	Philippine GMP standard; applies to manufacturers	IQ/OQ/PQ qualification lifecycle for storage areas

5. The Thermal Mapping Compliance Gap in Philippine Pharmaceutical Companies

Based on the regulatory requirements of FDA Circular 2021-003 and the state of practice in the Philippine pharmaceutical industry, there is a clear and significant compliance gap — one that affects a substantial proportion of Philippine drug establishments and creates real risk for both the businesses involved and the patients they serve.

The Gap Is Wider Than Most Companies Realise

The compliance gap with FDA Circular 2021-003’s thermal mapping requirements is not limited to small distributors or informal operators. It affects a significant portion of established, formally licensed pharmaceutical establishments — including some that have passed previous FDA inspections without being specifically challenged on thermal mapping documentation.

The reasons for this gap are understandable, if not excusable:

• Historical precedent: Under BFAD Circular 2007-003, the requirements were less explicit about storage area qualification. Many establishments built their compliance systems to the older standard and have not fully updated them.
• Misunderstanding of scope: Many establishments believe that having a temperature monitoring system is equivalent to having conducted thermal mapping. As we have discussed, these are entirely different requirements — one does not substitute for the other.
• Underestimation of inspection risk: Some establishments have not been specifically challenged on thermal mapping in previous FDA inspections and have concluded, incorrectly, that it is not a priority enforcement area. This conclusion is becoming increasingly dangerous as FDA enforcement focus sharpens.
• Cost perception: Thermal mapping is sometimes perceived as an expensive service with uncertain ROI. In reality, the cost of a mapping study is a fraction of the cost of a failed LTO renewal, a product recall, or a supply contract lost because a multinational principal has identified the gap.

Three Compliance Profiles — Where Does Your Company Sit?

Philippine pharmaceutical establishments typically fall into one of three compliance profiles relative to FDA Circular 2021-003’s thermal mapping requirements:

Profile	Characteristics	Risk Level	Recommended Action
Non-compliant	No thermal mapping conducted; temperature monitoring in place but no mapping study documentation; cold chain infrastructure not formally qualified	Critical — immediate LTO renewal risk; product quality risk	Conduct thermal mapping immediately for all storage areas; build documentation to FDA standard
Partially compliant	Some mapping conducted, often single-season only; older studies not updated after equipment changes; documentation gaps; sensors not positioned based on mapping data	High — may pass inspection on first review but vulnerable to detailed scrutiny	Conduct current-year seasonal mapping; update all documentation; reposition monitoring sensors based on mapping data
Compliant	Current seasonal mapping studies on file; sensors positioned at hot/cold spots; calibrated equipment with valid certificates; complete SOPs and training records; excursion management documented	Low — well-positioned for FDA inspection	Maintain schedule; ensure annual calibration; conduct remapping after changes; expand documentation quality

The LTO Renewal Risk Is Real and ImmediateFDA Administrative Order No. 2024-0015, implemented from January 2025, updated the requirements for Licence to Operate applications across all health product establishments. Drug distributors, importers, and pharmaceutical outlets applying for or renewing LTOs must demonstrate compliance with applicable quality and technical standards — including temperature storage requirements.An FDA inspector reviewing your LTO renewal application who asks for your thermal mapping documentation and finds none — or finds outdated, incomplete, or non-WHO-compliant studies — has grounds to recommend non-renewal or conditional renewal of your licence.For a pharmaceutical distribution business with an established product portfolio, loss of LTO is an existential event. The investment in proper thermal mapping is minuscule compared to this risk.

6. What FDA Inspectors Actually Look for Under Circular 2021-003

Understanding the inspection process helps pharmaceutical establishments prepare effectively. FDA inspectors evaluating compliance with Circular 2021-003 typically conduct a structured review of both physical infrastructure and documentation. Here is what they are looking for, in the order they typically conduct their review.

Physical Infrastructure Review

Inspectors will physically inspect storage areas to verify that the infrastructure matches what is documented. Key items checked include:

• Cold rooms and refrigerators are dedicated pharmaceutical units — not shared with food or non-pharmaceutical products
• Temperature monitoring devices are visibly installed and clearly operational
• Alarms are functioning — inspectors may ask you to demonstrate alarm activation
• Backup power is available and has been tested — generator test records should be available
• The physical layout of the storage area corresponds to the layout described in the thermal mapping report
• Products are not stored in zones identified as no-storage zones by the thermal mapping study

Documentation Review

The documentation review is typically the most detailed part of an FDA inspection under Circular 2021-003. Inspectors will request:

• Thermal mapping reports for all storage areas — complete, with all supporting documentation attached
• Study protocols — signed before the study began, not after
• Data logger calibration certificates — pre-study and ideally post-study; must show PAB-traceable calibration
• Monitoring sensor calibration certificates — current, with valid dates; must show ISO/IEC 17025-traceable calibration
• Temperature logs — continuous records for all monitored storage areas for the review period
• Temperature excursion records — every excursion event must be documented with an investigation report and product disposition decision
• SOPs — for all cold chain activities; approved and currently effective versions; training records for all relevant staff
• Equipment maintenance records — for cold rooms, refrigerators, HVAC systems, and monitoring equipment
• Seasonal mapping evidence — studies conducted in both dry season and wet season conditions

The Questions Inspectors Ask

In addition to reviewing physical infrastructure and documentation, FDA inspectors typically ask specific questions of QA personnel and facility managers. Being prepared to answer these questions fluently — with documentary evidence immediately available — makes the difference between a smooth inspection and a deficiency finding:

• “When was your last thermal mapping study conducted?” — Answer should reference a specific date within the past year or two, with the report immediately producible.
• “Was the study conducted in both the dry season and wet season?” — Both studies should be on file.
• “Where are your permanent monitoring sensors positioned, and why?” — The answer must reference the hot spot and cold spot identified by the mapping study.
• “What is your procedure when a temperature alarm activates?” — The SOP must be described accurately and the training records must support that staff know the procedure.
• “What happened the last time you had a temperature excursion?” — There should be a documented investigation report with a product disposition decision for every excursion event.
• “Who calibrates your temperature monitoring equipment, and when was the last calibration?” — The calibrator must be PAB-accredited; the certificate must be current and on file.

7. Philippine-Specific Challenges That Make Compliance Harder — and More Important

The Philippines presents a combination of environmental, infrastructural, and operational challenges that make pharmaceutical cold chain compliance both more difficult and more critical than in many other markets.

The Tropical Climate Challenge

The Philippines sits between 5°N and 21°N latitude, entirely within the tropical zone. Average temperatures of 26°C to 32°C, with seasonal peaks above 35°C in many parts of Luzon, combined with relative humidity regularly exceeding 80%, create one of the most demanding environments in the world for maintaining pharmaceutical-grade controlled room temperature storage.

For drug distributors operating large ambient-temperature warehouses, maintaining the 15°C to 30°C controlled room temperature range (or ideally 20°C to 25°C for CRT products) throughout a warehouse volume in Metro Manila in April — when ambient temperatures routinely exceed 34°C and cooling systems are under maximum stress — is a genuine engineering challenge. Thermal mapping under these peak-season conditions is not a regulatory formality. It is a test of whether your HVAC system is actually capable of doing its job when it matters most.

The Power Interruption Challenge

Power interruptions remain a significant operational reality for pharmaceutical facilities outside Metro Manila and in many parts of Metro Manila itself. The circular’s requirement for backup power — generator sets and voltage regulators — directly addresses this risk. But the requirement goes further: backup power systems must be tested, and the results of those tests must document how quickly temperature recovers after a power interruption.

Thermal mapping studies include a power failure test — a deliberate interruption of cooling to measure how quickly temperatures rise to out-of-specification levels. This data directly informs how long your facility has to respond to a real power interruption before products are at risk. For a facility in an area with frequent power interruptions, this is one of the most practically important outputs of the thermal mapping study.

The Archipelago Distribution Challenge

Distributing pharmaceutical products across 7,641 islands — from the Ilocos Region to Mindanao, from Palawan to Samar — while maintaining cold chain integrity is a logistical challenge with few parallels anywhere in the world. Port handling conditions, inter-island transport, last-mile delivery in areas with limited cold chain infrastructure, and the risk of temperature excursion at every handoff point make the Philippine pharmaceutical cold chain one of the most complex in Southeast Asia.

FDA Circular 2021-003 addresses not only storage but the entire cold chain — from origin to patient. Transport cold chain management, including qualification of transport vehicles and containers, is within the scope of the circular’s requirements. Establishing a thermal mapping programme for your storage facilities is the foundation, but a complete compliance programme addresses the full distribution chain.

8. A Practical Compliance Roadmap for Philippine Drug Companies

Building FDA Circular 2021-003 compliance from scratch — or closing the gaps in a partially compliant system — requires a structured approach. Here is a practical roadmap that Metrologie Solutions Philippines recommends for pharmaceutical establishments at different stages of readiness.

For Non-Compliant Establishments: Immediate Priority Actions

6. Conduct an internal gap assessment — map your current storage areas, equipment, monitoring systems, and documentation against the requirements of the circular and identify every gap.
7. Engage a specialist thermal mapping service provider — for all cold rooms, refrigerated storage, and ambient warehouses used for pharmaceutical products. Do not wait. Every day of operation without qualified storage areas is a day of non-compliance with FDA Circular 2021-003.
8. During the mapping study, conduct a power failure test for cold storage areas — and document the results to inform your excursion response SOP.
9. Use the mapping results to reposition permanent monitoring sensors at the identified hot spots and cold spots.
10. Develop and approve all required SOPs — cold chain management, temperature monitoring, excursion response, equipment maintenance, calibration, and product disposition.
11. Establish a calibration schedule for all monitoring equipment and engage a PAB-accredited calibration laboratory.
12. Train all relevant personnel on the new SOPs and retain training records.

For Partially Compliant Establishments: Gap-Closing Actions

13. Review existing thermal mapping documentation — is it current? Was it conducted in both seasons? Were sensors positioned based on mapping data? Does the report meet WHO documentation standards?
14. Conduct seasonal remapping if your current studies are more than two years old, were conducted in only one season, or were done with non-traceable calibration equipment.
15. Verify that monitoring sensor positions match the hot spots and cold spots from your most recent mapping study — and reposition sensors if they do not.
16. Audit all SOP documentation for completeness, current approval status, and training compliance.
17. Ensure all calibration certificates are current and from a PAB-accredited laboratory.
18. Review your excursion records — are all events documented with investigation reports and product disposition decisions?

For Compliant Establishments: Maintaining and Strengthening Compliance

19. Maintain your mapping schedule — conduct seasonal studies (dry season and wet season) and schedule remapping at least every two years.
20. Review and update SOPs annually or whenever operational changes occur.
21. Ensure calibration is on schedule for all monitoring equipment — annually at minimum, every six months for high-risk products.
22. Conduct periodic mock inspections or internal audits against the FDA Circular 2021-003 requirements to identify emerging gaps before they become inspection findings.
23. Document all changes to storage infrastructure in a change control log, and assess each change for its potential impact on thermal mapping validity.

The 90-Day Priority Action PlanIf your establishment is non-compliant or partially compliant with FDA Circular 2021-003’s thermal mapping requirements, here is a 90-day action plan:Days 1-10: Internal gap assessment and engagement of qualified thermal mapping service providerDays 10-30: Thermal mapping study conducted (including power failure testing) for all storage areasDays 30-50: Mapping report finalised, approved, and filed; monitoring sensors repositioned based on mapping dataDays 50-75: SOPs developed/updated; calibration schedule established; calibration certificates obtainedDays 75-90: All personnel trained on updated SOPs; training records completed; compliance documentation package assembled

9. Frequently Asked Questions: FDA Circular 2021-003 and Thermal Mapping

Does FDA Circular 2021-003 specifically use the term ‘thermal mapping’?

The circular’s language aligns with the WHO Good Distribution Practice guidelines it references, which use terms such as ‘qualification,’ ‘validation,’ and ‘temperature mapping.’ The requirement to conduct a documented qualification study of storage areas — demonstrating temperature uniformity and identifying hot and cold spots — is the thermal mapping requirement, regardless of the specific terminology used. FDA inspectors who are familiar with the WHO guidelines (as the Philippine FDA’s most experienced inspectors are) understand this connection clearly.

Our establishment only stores ambient temperature products — do we still need thermal mapping?

Yes. Ambient-temperature warehouses storing pharmaceutical products in the Philippines face significant temperature control challenges due to the tropical climate. A controlled room temperature warehouse that cannot maintain temperatures within 15°C to 30°C — or ideally 20°C to 25°C — throughout its entire volume is not compliant. The only way to demonstrate compliance is through a thermal mapping study that proves every part of the warehouse stays within range under the most challenging conditions, including peak summer temperatures. Summer season mapping (March to May) is particularly important for ambient temperature warehouses in the Philippines.

We passed our last FDA inspection without being asked about thermal mapping. Does that mean we are compliant?

Not necessarily. FDA inspection thoroughness varies, and the absence of a finding in a previous inspection does not mean the requirement did not exist or does not apply to you. FDA Circular 2021-003 has been in effect since 2021, and AO 2024-0015 has sharpened the LTO compliance requirements since January 2025. The enforcement landscape is changing, and relying on historical inspection experience to assess current compliance risk is not a sound strategy.

How long do we need to keep thermal mapping records?

Pharmaceutical documentation retention requirements in the Philippines follow the principle that records must be retained for the life of the product plus a reasonable additional period. For temperature qualification records that are part of your quality management system’s infrastructure documentation, retention for the operational life of the storage facility plus a minimum of five years is the prudent standard. Your quality SOP should specify the retention period applicable to your establishment type and product portfolio.

Our cold room was installed five years ago and has never been thermally mapped. What is our priority?

Immediate mapping is your highest priority. Every day you operate a pharmaceutical storage area without qualification documentation is a day of non-compliance with FDA Circular 2021-003. Engage a specialist thermal mapping service provider as soon as possible. While you are waiting for the study to be scheduled and conducted, ensure that your continuous temperature monitoring system is functioning, calibrated, and generating complete records — this at least demonstrates that you are actively managing temperature control even while the formal qualification study is pending.

Can the same thermal mapping service provider also supply and calibrate our monitoring equipment?

Yes, and this is often a more efficient approach. Working with a single provider who offers both thermal mapping services and temperature monitoring calibration ensures consistency in measurement traceability, simplifies the documentation process, and gives you a single point of accountability for your cold chain compliance documentation. Metrologie Solutions Philippines offers both services — thermal mapping studies and PAB-traceable calibration of monitoring equipment — as part of a comprehensive cold chain compliance programme.

Conclusion: FDA Circular 2021-003 Is Not Optional — Neither Is Thermal Mapping

FDA Circular No. 2021-003 is the law of the Philippine pharmaceutical cold chain. It is not a guideline, a recommendation, or a best practice framework. It is the regulatory standard against which every covered pharmaceutical establishment in the Philippines is evaluated — when applying for a Licence to Operate, when undergoing an FDA inspection, and when its products are evaluated for quality and integrity in the market.

Thermal mapping — the documentation of temperature distribution throughout your storage areas, conducted with calibrated equipment and documented to WHO standards — is not a technical nicety within this framework. It is one of its core requirements. An establishment that stores pharmaceutical products in storage areas that have never been thermally mapped is operating on an unvalidated foundation: it may believe its storage is compliant, but it cannot prove it. And in pharmaceutical regulation, proof is everything.

The Philippine FDA’s alignment with WHO Good Distribution Practice guidelines, formalised through FDA Circular 2021-003, means that the thermal mapping standard applicable to your Philippine pharmaceutical warehouse is the same standard applied to pharmaceutical facilities in Singapore, Japan, Europe, and the United States. The international pharmaceutical community has converged on this standard because it works — because a storage area that has been properly mapped, with sensors positioned at the worst-case locations and continuous monitoring running 24 hours a day, is a storage area that actually protects the products stored within it.

Metrologie Solutions Philippines is ready to help your establishment achieve and demonstrate full compliance with FDA Circular 2021-003’s thermal mapping requirements. Our studies are conducted with PAB-traceable calibration, documented to WHO TRS 961 Supplement 8 standards, and designed to produce documentation that will satisfy the most rigorous FDA inspection.

Contact Metrologie Solutions Philippines TodayWhether your establishment needs an immediate first-time thermal mapping study, a seasonal remapping to update outdated documentation, or a comprehensive compliance programme covering mapping, monitoring calibration, and SOP development — our team is ready to help.We serve drug manufacturers, importers, distributors, hospital pharmacies, and cold chain operators across the Philippines, from Metro Manila to Mindanao.Website: metrologiesolutions.com   |   Services: Thermal Mapping · Calibration · Training · Cold Chain Compliance Consulting

About Metrologie Solutions PhilippinesMetrologie Solutions Philippines is the country’s leading authority on thermal mapping, instrument calibration, and pharmaceutical cold chain compliance. We help drug manufacturers, importers, distributors, hospital pharmacies, and cold chain logistics providers across the Philippines achieve and maintain full compliance with FDA Circular No. 2021-003, WHO Good Distribution Practice guidelines, and GMP requirements. Every study we deliver is documented to the standard that survives the most rigorous FDA inspection.Website: metrologiesolutions.com   |   Services: Thermal Mapping · Calibration · Training · Cold Chain Consulting

Tags: FDA Circular 2021-003 Philippines, FDA 2021-003 cold chain requirements, thermal mapping pharmaceutical Philippines, pharmaceutical cold chain compliance Philippines, drug distributor cold chain Philippines, FDA Philippines temperature mapping, LTO requirements pharmaceutical Philippines, WHO GDP Philippines, temperature mapping drug company Philippines, pharmaceutical warehouse qualification Philippines, PAB accredited calibration Philippines, Metrologie Solutions Philippines